4.005USD-0.99%Mkt Cap: 283.68M USDP/E: —Last update: 2026-06-01
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenose…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap283.68M USD
Enterprise Value107.64M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-137.06M USD
Revenue/Share—
Last Price4.005 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.57
PEG—
EV/EBITDA-0.77
EV/Revenue—
P/S—
P/B1.28
EPS (TTM)-1.74
EPS (Forward)-1.56
52W Range
1.13049% of range6.950
52W High6.950 USD
52W Low1.130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-63.39%
ROA-47.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-125.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-25.85%
Net Debt-177.11M USD
Net Debt/EBITDA1.26
Balance Sheet
Debt/Equity0.17
Current Ratio6.19
Quick Ratio6.01
Book Value/Sh3.129 USD
Cash/Share2.975 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)6.500 USD
Target Range4.000 USD – 10.00 USD
# Analysts8
Ownership
Shares Out.71.19M
Float48.84M
Insiders22.44%
Institutions62.06%
Short Interest
Short Ratio4.0d
Short % Float8.66%
Short % Out.6.92%
Shares Short4.92M
Short (prev mo.)5.20M
Technical
SMA 503.781 (+5.9%)
SMA 2002.363 (+69.5%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)1.00M
Avg Vol (10d)988.37K
Technical Indicators
RSI (14)51.7
MACD0.0244
MACD Signal0.0450
MACD Hist.-0.0206
BB Upper4.477 USD
BB Middle4.047 USD
BB Lower3.617 USD
BB Width21.26%
ATR (14)0.3239 USD
Vol Ratio (20d)0.31x